Leerink Swann Initiates Coverage on Synthorx (THOR)

Equities research analysts at Leerink Swann assumed coverage on shares of Synthorx (NASDAQ:THOR) in a report issued on Friday, The Fly reports. The firm set an “outperform” rating on the medical instruments supplier’s stock.

THOR has been the subject of a number of other reports. Jefferies Financial Group initiated coverage on shares of Synthorx in a research report on Wednesday, January 2nd. They set a “buy” rating and a $21.00 price target for the company. HC Wainwright initiated coverage on shares of Synthorx in a research report on Wednesday, January 2nd. They set a “buy” rating and a $30.00 price target for the company.

THOR opened at $18.25 on Friday. The firm has a market cap of $488.90 million and a PE ratio of -2.77. Synthorx has a one year low of $11.00 and a one year high of $23.53.

Synthorx (NASDAQ:THOR) last released its quarterly earnings results on Tuesday, March 12th. The medical instruments supplier reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.77). As a group, sell-side analysts anticipate that Synthorx will post -1.62 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Matisse Capital bought a new stake in shares of Synthorx during the 4th quarter worth $956,000. Monashee Investment Management LLC bought a new stake in shares of Synthorx during the 4th quarter worth $435,000. Dean Capital Investments Management LLC bought a new stake in shares of Synthorx during the 4th quarter worth $827,000. FMR LLC bought a new stake in shares of Synthorx during the 4th quarter worth $38,559,000. Finally, RA Capital Management LLC bought a new stake in shares of Synthorx during the 4th quarter worth $169,014,000. 75.85% of the stock is owned by institutional investors.

About Synthorx

Synthorx, Inc, a biotechnology company, discovers and develops protein therapeutics. The company's lead product candidate is THOR-707, a variant of IL-2 that is in development in various tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded in 2014 and is headquartered in La Jolla, California.

Further Reading: Return on Equity (ROE)

The Fly

Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.